^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SAR260301

    i
    Other names: SAR260301
    Associations

    News

    Trials
    Company:
    Sanofi
    Drug class:
    PI3K inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    circSCAP-encoded SCAP-129aa mediates platinum resistance in triple-negative breast cancer via the PI3K/AKT pathway. (PubMed, Sci China Life Sci)
    Notably, in vivo studies further indicated that either silencing circSCAP or co-administering the PIK3R2 inhibitor SAR-260301 with platinum significantly improves treatment efficacy in resistant TNBC models. These findings establish circSCAP and SCAP-129aa as promising biomarkers and potential therapeutic targets for overcoming platinum resistance in TNBC.
    Journal
    |
    PIK3R2 (Phosphoinositide-3-Kinase Regulatory Subunit 2 )
    |
    SAR260301